Interleukin-6 displays lung anti-inflammatory properties and exerts protective hemodynamic effects in a double-hit murine acute lung injury

Guillaume Voiriot\textsuperscript{1,2,*}, Keyvan Razazi\textsuperscript{1,2,3}, Valérie Amsellem\textsuperscript{1}, Jeanne Tran Van Nhieu\textsuperscript{2,4}, Shariq Abid\textsuperscript{1}, Serge Adnot\textsuperscript{1,2,5}, Armand Mekontso Dessap\textsuperscript{1,2,3†} and Bernard Maitre\textsuperscript{1,2,3†}

\textbf{Abstract}

\textbf{Background:} Interleukin 6 (IL-6) is a predictive factor of poor prognosis in patients with acute respiratory distress syndrome (ARDS). However, its acute pulmonary hemodynamic effects and role in lung injury have not been investigated in a clinically relevant murine model of ARDS.

\textbf{Methods:} We used adult C57Bl6 wild-type (WT) and IL-6 knock-out (IL-6KO) mice. The animals received intravenous recombinant human IL-6 (rHuIL-6) or vehicle followed by intratracheal lipopolysaccharide (LPS) or saline before undergoing low tidal volume mechanical ventilation (MV) for 5 h. Before sacrifice, right ventricular systolic pressure and cardiac output were measured and total pulmonary resistance was calculated. After sacrifice, lung inflammation, edema and injury were assessed with bronchoalveolar lavage (BAL) and histology. In other experiments, right ventricular systolic pressure was recorded during hypoxic challenges in uninjured WT mice pretreated with rHuIL-6 or rHuIL-6 + non-selective nitric oxide synthase inhibitor L-NAME or vehicle.

\textbf{Results:} IL-6KO\textsubscript{LPS+MV} mice showed a faster deterioration of lung elastic properties and more severe bronchoalveolar cellular inflammation as compared to WT\textsubscript{LPS+MV}. Treatment with rHuIL-6 partially prevented this lung deterioration. Total pulmonary resistance was higher in IL-6KO\textsubscript{LPS+MV} mice and this increase was abolished in rHuIL-6-treated IL-6KO mice. Finally, rHuIL-6 reduced hypoxic pulmonary vasoconstriction in uninjured WT mice, an effect that was abolished by co-treatment with L-NAME.

\textbf{Conclusions:} In a double-hit murine model of ARDS, IL-6 deficient mice experienced more severe bronchoalveolar cellular inflammation as compared to wild-type littermates. Furthermore, IL-6 deficiency caused marked acute pulmonary hypertension, which may be, at least partially, due to vasoactive mechanisms. A dysregulation of nitric oxide synthase may account for this observation, a hypothesis that will need to be investigated in future studies.

\textbf{Keywords:} Interleukin-6, Acute lung injury, Acute respiratory distress syndrome, Mechanical ventilation, Pulmonary hypertension, Nitric oxide synthase
Background
Acute Respiratory Distress Syndrome (ARDS) is a life-threatening syndrome consisting of acute onset respiratory failure caused by noncardiogenic edema and characterized by hypoxemia and radiological bilateral lung infiltrates [1]. The pathology includes alveolocapillary membrane abnormalities due to various agents either inhaled or delivered to the lungs via the blood circulation [2]. The pathogenesis involves a potent inflammatory response, involving a complex group of mediators including interleukin-6 (IL-6). This pleiotropic cytokine is produced at sites of tissue inflammation and released into the circulation by a variety of different cell types, including macrophages, lymphocytes, endothelial cells, epithelial cells and fibroblasts [3] during sepsis and acute organ injuries. IL-6 acts as a major pro-inflammatory mediator for the induction of the acute phase response [4], leading to a wide range of local and systemic changes including fever, leucocytes recruitment and activation, hepatic regeneration and hemodynamic effects. Considering the key role of IL-6 in mediating the acute phase response, its value as a prognostic biomarker in sepsis and various acute organ injuries has been extensively investigated in clinical and experimental studies. Plasma and/or broncho-alveolar levels of IL-6 have been identified as early biomarkers of lung injury [5–8] and predictive factors of prolonged mechanical ventilation, organ dysfunctions, morbidity and mortality in ARDS [9–12]. However, whether the increased plasma or tissue levels of IL-6 observed in sepsis and ALI/ARDS, contribute to organ injury, prevent it or merely describe it, remains controversial [13]. Indeed, beneficial anti-inflammatory effects of IL-6 have been shown in experimental lung injury [14–16]. This hypothesis has not been tested in a lung injury model closely relevant to the clinical situation. Furthermore, the pulmonary hemodynamic effects of IL-6 in ARDS remain unclear, even though pulmonary vascular dysfunction is a major hallmark of ARDS [17]. In this study, we used a double-hit, clinically relevant murine model of ARDS combining lipopolysaccharide (LPS) aspiration followed by 5-h low tidal volume mechanical ventilation. We applied this model to IL-6 gene knock-out mice to assess the effects of IL-6 during ARDS on respiratory mechanics, lung inflammation, and right-sided ventricular hemodynamics.

Methods

Animals
Mice lacking IL-6 (IL-6−/−) were generated by homologous recombination on the C57Bl/6 and IL-6−/− genetic background [18]. The wild-type IL-6+/+ mice (WT mice) and mutant homozygous knock-out IL-6−/− mice (IL-6KO mice) were adult male littermates obtained by breeding heterozygous mutants. All animal care and procedures were performed after approval of the Institutional Animal Care Committee, in accordance with official guidelines of the French Ministry of Agriculture for the experimental use of animals.

Animal protocol
Mice were anesthetized with inhaled 5% isoflurane (Abbott, Rungis France) and were maintained spontaneously breathing. They received retro-orbital intravenous injections [19] of either 3 μg/kg of recombinant human IL-6 (rHuIL-6, PromoCell, Heidelberg, Germany) or vehicle (saline). Following the injection, 2 μL/g of body weight volume instillate consisting of 2 μg/μL of Escherichia coli O55:B5-derived LPS (Sigma-Aldrich Chimie, Lyon, France) or vehicle (saline) was administered into the distal part of the oropharynx and aspirated into the lower respiratory tract. The selection of rHuIL-6 doses was based on previously published studies with intravenous rHuIL-6 in mouse models of sepsis [20] and acute myocardial infarction [21]. Following recovery from anesthesia, the mice were returned to their cage with free access to water and food.

Eighteen hours later, mice were anesthetized with a combination of intraperitoneal pentobarbital (30 μg/g of body weight, Hospira, Meudon La Forêt, France) and inhaled 5% isoflurane (Abbott, Rungis France). Following a second intravenous injection of rHuIL-6 (identical to the first injection) or vehicle, the larynx was surgically exposed and the trachea intubated orally under direct vision with a metal cannula (internal diameter of 1 mm, Harvard Apparatus, Les Ulis, France). The tracheal cannula was properly secured with surgical thread (Ethicon 3–0, Ethicon, Auneau, France) before being connected to a mechanical ventilator. The cervicotomy was closed with surgical thread (Ethicon 6.0, Ethicon, Auneau, France).

Mechanical ventilation
The ventilator regimen has been extensively detailed elsewhere [22]. Briefly, mice were ventilated in the supine position using humidified gas (20 mgH2O/L ab- solute humidity, MR410 humidifier, Fischer & Paykel Healthcare, Courtaboeuf, France), with a tidal volume of 8 mL/kg of body weight, a respiratory rate of 180/min, 3 cmH2O end-expiratory pressure, and FiO2 of 0.5, by means of a computer-driven small-animal ventilator (flexiVent, Scireq, Montreal, Canada). Mechanical ventilation lasted 5 h with continuous anesthesia maintained by 1.5% isoflurane and muscle paralysis using intraperitoneal pancuronium given at the onset of mechanical ventilation and then every two hours (0.8 μg/g of body weight, Organon, Puteaux, France) to ensure passive mechanical conditions. Mice received intraperitoneal warm fluid boluses (5% dextrose with 9 g/L NaCl) at the onset (20 μL/g of body weight) and every hour (10 μL/g of body weight) during mechanical ventilation.
Experimental design
The experimental design included six groups: WT (WT receiving saline instillation and vehicle injections and undergoing mechanical ventilation (MV)), WT (WT mice receiving LPS instillation and vehicle injections and undergoing mechanical ventilation), WT + rHuIL-6 (WT mice receiving LPS instillation and rHuIL-6 injections and undergoing mechanical ventilation), IL-6KO (IL-6KO mice receiving saline instillation and vehicle injections and undergoing mechanical ventilation), IL-6KO (IL-6KO mice receiving LPS instillation and vehicle injections and undergoing mechanical ventilation) and IL-6KO + rHuIL-6 (IL-6KO mice receiving LPS instillation and rHuIL-6 injections undergoing mechanical ventilation).

Model assessment
To contrast the effects of the double-hit challenge (LPS + mechanical ventilation) with those of either LPS administration alone, we subjected wild-type C57BL6 adult male mice to LPS or vehicle (saline) aspiration without mechanical ventilation. We then assessed lung injury and measured total cell count, and total protein, IL-6, TNFα and MIP-2 concentrations in BAL fluid as described below.

Respiratory mechanics
Special features of the flexiVent ventilator include a continuous monitoring of airway pressures and a precision computer-controlled piston capable of accurately measuring the delivered volume (with appropriate corrections for gas compression) and producing any desired waveform, allowing respiratory mechanics assessment with the forced oscillation technique (FOT) and pressure-volume curves [22]. Following a stabilization period of 5 min, mice were inflated twice to a transrespiratory pressure of 30 cmH2O to establish a standard volume history. Peak inspiratory pressure was measured at initiation of mechanical ventilation, before and after volume history standardization, and then hourly. Respiratory system dynamic compliance and elastance were measured using the single frequency FOT at initiation of mechanical ventilation, before and after volume history standardization, and then hourly to capture the time course and detailed response to mechanical ventilation. The respiratory system quasi-static compliance was measured using a pressure-driven pressure-volume curve at start (before and after volume history standardization) and end of mechanical ventilation. Before the end of the timed ventilator protocol, mice underwent hemodynamic measurements [22].

Hemodynamic measurements
Both the right jugular vein and left carotid artery were isolated through the cervical midline incision using a stereomicroscope (Leica MZ 7.5, Leica Microsystems, Nanterre, France). An ultra-miniature 0.47 mm high fidelity pressure transducer catheter (SPR-671, Millar Instruments, Houston, TX) was inserted into the right jugular vein and advanced into the right ventricle. The micromanometer was calibrated in vitro, firstly electronically and secondly against a column of mercury with the reference zero level taken at mid chest. Right ventricular systolic pressure was measured during a short end-expiratory ventilatory pause using a Gould transducer (Gould, Cleveland, USA) and a Notocord system (Emka Technologies, Paris, France). Cardiac output was measured with the transpulmonary thermodilution technique [23]. Briefly, a 0.34 mm external diameter thermistor microprobe (Columbus Instruments, Columbus, OH) was inserted into the left carotid artery and advanced into the aortic arch, where changes in aortic blood temperature were measured. A 0.5 mm external diameter catheter placed in the right jugular vein was advanced into the right atrium for bolus injection of 20 μL of NaCl 9 g/L solution at 20°C. Five consecutive cardiac output measurements were obtained using the Cardiomax-III system (Columbus Instruments) and total pulmonary resistance was calculated as the ratio of right ventricular systolic pressure to cardiac output.

Specimen collection
At the end of the timed ventilation protocol and after completion of hemodynamic measurements, mice were exsanguinated via sectioning of the left carotid artery. Arterial blood gases were determined in five WT (LPS+MV) group mice. Bronchoalveolar lavage (BAL) was performed with four separate 0.5 mL aliquots of saline at 20 °C followed by lung fixation (paraformaldehyde 4%, inflation pressure 25 cmH2O for 1 min) and paraffin embedding. The total cell count of BAL fluid was determined from a fresh BAL fluid specimen using a Malassez hemocytometer. The BAL fluid was centrifuged (1600 rpm, 7 min at 4°C), the cell pellet was diluted in saline, and differential cell counts were done in four WT (LPS+MV) mice and four IL-6KO (LPS+MV) mice on cytocentrifuge preparations (Cytospin 3; Shandon Scientific, Cheshire, UK) stained with Diff-Quick (Baxter Diagnostics, McGaw Park, IL). Cell-free supernatants were stored at ~80°C for subsequent duplicate measurements of total protein (Bio-Rad Protein Assay) and cytokine concentrations [macrophage inflammatory protein 2 (MIP-2), tumor necrosis factor α (TNF-α) and IL-6 using an ELISA immunoassay kit, (R&D systems, Abingdon, UK) performed in accordance with manufacturer’s instructions.

Histological analysis
Paraffin lungs blocks were sectioned at 5μm thickness and mounted on glass slides. After staining with hematoxylin and eosin, all slides were examined under a light microscope by an experienced pathologist in a blinded fashion.
Lung injury was assessed using a histological scoring system designed to evaluate the heterogeneous lesions of lung injury and adapted from previously published scores [24, 25]. Three pathological processes (edema, congestion/hemorrhage and leukocyte infiltration) were scored in the two main non-alveolar structures of the lung (veins and bronchi/arteries) using the two following scales: 1) an intensity scale (0 to 4: 0 if absent, 1 if mild, 2 if moderate, 3 if severe, and 4 if very severe), and 2) an extension scale (0 if absent, 1 if <25% of lung involvement, 2 if 25–50% of lung involvement, 3 if 50–75% of lung involvement, and 4 if >75% of lung involvement). Three pathological processes (thickness of the alveolar wall, neutrophil recruitment in airspace, and macrophage aggregation in airspaces) were scored in the alveoli using the same scales as above. A composite score of intensity and extension (intensity score times extension score) was calculated for each pathological process in each structure. The resulting values (0 to 16) were added to yield partial scores of edema in veins and bronchi/arteries (0 to 32), congestion/hemorrhage in veins and bronchi/arteries (0 to 32), leukocyte infiltration (0 to 48, associating leukocyte infiltration in veins and bronchi/arteries and thickness of the alveolar wall) and alveolitis (0 to 32, associating neutrophil aggregation and macrophage aggregation in airspaces). Finally, the four partial scores were added to yield a global lung injury score (0 to 144).

**Acute hypoxic challenge**

The effects of IL-6 on pulmonary vascular reactivity were evaluated using acute hypoxic challenge. Briefly, three groups of wild-type adult male C57Bl6 mice were randomly assigned to receive rHuIL-6 + L-NAME (Nω-nitro-L-arginine methyl ester hydrochloride), rHuIL-6 + vehicle or vehicle + vehicle administered as follows: rHuIL-6 (3μg/kg of body weight) or vehicle (NaCl 9 g/L) via retro-orbital intravenous injection and L-NAME (50 μg/g of body weight, Sigma-Aldrich Chimie, Lyon, France) or vehicle (NaCl 9 g/L) intraperitoneally. Five hours later, mice were anesthetized and intubated for mechanical ventilation. A Millar transducer catheter was immediately inserted and advanced into the right ventricle. After thirty minutes of stabilization, the right ventricular systolic pressure was continuously recorded during four consecutive hypoxic challenges (FiO2 of 0.08 during 2 min, followed by 5 min of reoxygenation).

**Statistics**

The data were analyzed using the SPSS Base 18.0 statistical software package (SPSS Inc, Chicago, IL). Normality of continuous data was assessed with the Kolmogorov Smirnov test. Because not all data sets were normally distributed we used the median [1st quartile - 3rd quartile] for descriptive statistics unless otherwise stated. Independent samples were compared using the Kruskal-Wallis test followed by a pairwise Mann-Whitney test, with correction for multiple testing by the Benjamini-Hochberg false discovery rate test. Two-tailed p values smaller than 0.05 were considered significant.

**Results**

**Animals and procedures**

Mice were 18 [14–22] weeks old and weighted 26 [25–29] g. Each group included 8 to 10 animals. All animals survived the protocol.

**Model assessment**

Results are reported in Fig. 1. As compared to mice undergoing mechanical ventilation alone (MV group), mice subjected to both LPS and mechanical ventilation (LPS + MV group) showed higher lung injury score, higher total cell count and higher total protein, IL-6, TNFα and MIP-2 concentrations in BAL fluid. As compared to mice receiving LPS alone (LPS group), mice subjected to both LPS and mechanical ventilation (LPS + MV group) showed a higher total cell count and higher total protein, IL-6, and MIP-2 concentrations in BAL fluid.

**Respiratory mechanics**

The ventilator settings allowed a tight control of minute ventilation, and partial arterial CO2 pressure as determined in five animals in the WT (LPS+MV) group (39 [33–43] mmHg). Results of airway pressure monitoring, forced oscillation techniques and pressure-volume curves are shown in Table 1 and Fig. 2. Baseline respiratory mechanics differed slightly between WT and IL-6KO mice. We found a lower quasi-static compliance in IL-6KO mice as compared to WT mice (101 [97–103] vs. 108 [106–112]; p < 0.001) at initiation of mechanical ventilation (after volume history standardization) (Fig. 2b), whereas we noted no differences in other parameters of respiratory mechanics. This phenotypic difference in quasi-static compliance between WT and IL-6KO mice was also observed in mice subjected to LPS aspiration with or without injections of rHuIL-6.

At initiation of mechanical ventilation, LPS aspiration was associated with an alteration of respiratory mechanics (lower quasi-static and dynamic compliances, higher dynamic elastance and peak inspiratory pressure) as compared to saline aspiration in both WT (WT (LPS+MV) vs. WT (MV)) and IL-6KO mice (IL-6KO (LPS+MV) vs. IL-6KO (MV)). These differences were not altered by injections of rHuIL-6. We assessed the relative decrease in the quasi-static compliance during the ventilator protocol as previously described. We found a greater alteration in lung compliance in mice exposed to LPS + MV as compared to mice exposed to mechanical ventilation alone (~25.9%
[–31.7;–15.1] in WT (MV) vs. [–37.4% [–40.0;–35.4]% in WT (LPS+MV), p = 0.001; [–18.7% [–29.7;–9.8]% in IL-6KO (MV) vs. [–33.3% [–37.7;–28.1]% in IL-6KO (LPS+MV), p = 0.011], without any difference between WT and IL-6KO mice.

During mechanical ventilation, dynamic elastance and peak airways pressures increased, whereas dynamic and quasi-static compliances decreased. The progressive deterioration of respiratory mechanics was seen in both IL-6KO and WT mice but was greater in LPS-challenged mice (WT (LPS+MV) and IL-6KO (LPS+MV)) as compared to saline-treated mice (WT (MV) and IL-6KO (MV)). Furthermore, the progressive deterioration of respiratory mechanics was faster in IL-6KO (LPS+MV) mice as compared to WT (LPS+MV) mice, as shown by differences in dynamic elastance at H1 (65 [59–83] vs. 56

Table 1 Respiratory mechanics at start (H0) and after a 5-h (H5) of low tidal volume mechanical ventilation (MV) following a lipopolysaccharide (LPS) or vehicle (saline) aspiration in wild type (WT) and interleukin-6 knock-out (IL-6KO) mice, receiving either recombinant human interleukin-6 (rHuIL-6) or vehicle (saline)

|                | WT(MV) | WT(LPS+MV) | WT + rHuIL-6 | IL-6KO(MV) | IL-6KO(LPS+MV) | IL-6KO + rHuIL-6 |
|----------------|--------|------------|--------------|------------|----------------|-----------------|
| Peak Pr H0 post-VHS | 10.5 (10.3–11.0) | 11.6 (11.3–12.0) | 12.0 (11.6–12.5) | 10.7 (10.1–10.9) | 11.6 (11.3–12.4) | 12.0 (11.4–13.6) |
| Peak Pr H5    | 17.7 (16.3–18.3) | 21.5 (20.5–22.0) | 22.6 (22.3–23.5) | 17.3 (15.6–18.5) | 21.3 (20.0–22.5) | 20.9 (20.6–22.4) |
| Cstat H0 pre-VHS | 96 (93–106) | 67 (54–73) | 65 (58–69) | 92 (82–99) | 51 (47–62) | 54 (49–62) |
| Cstat H0 post-VHS | 108 (106–112) | 80 (65–88) | 78 (70–83) | 101 (97–103) | 60 (56–65) | 64 (57–68) |
| Cstat H5    | 82 (75–82) | 49 (41–54) | 43 (38–50) | 78 (71–92) | 41 (38–47) | 43 (42–50) |
| Cdyn H0 pre-VHS | 32 (30–35) | 22 (18–25) | 24 (23–26) | 31 (27–35) | 23 (20–27) | 26 (22–28) |
| Cdyn H0 post-VHS | 53 (49–57) | 32 (30–36) | 34 (30–36) | 53 (49–54) | 32 (27–40) | 35 (31–37) |
| Cdyn H5    | 21 (19–23) | 13 (12–14) | 13 (11–14) | 22 (19–28) | 12 (12–14) | 15 (13–15) |
| Edyn H0 pre-VHS | 31 (29–33) | 45 (40–55) | 44 (39–46) | 33 (29–37) | 43 (37–49) | 39 (37–46) |
| Edyn H0 post-VHS | 19 (18–20) | 32 (28–33) | 30 (29–33) | 19 (19–21) | 32 (25–37) | 29 (27–33) |
| Edyn H5    | 48 (45–53) | 78 (72–86) | 75 (72–90) | 47 (36–52) | 82 (71–85) | 68 (67–75) |

Data are presented as median [25th–75th percentile].

Abbreviations: Peak Pr peak inspiratory pressures, Cstat quasi-static compliance of the respiratory system (calculated using a pressure-volume curve), Cdyn dynamic compliance of the respiratory system (calculated using the single frequency forced oscillation technique), Edyn dynamic elastance of the respiratory system (calculated using the single frequency forced oscillation technique). Volume history standardization (VHS) consisted in two inflations to an airway pressure of 30 cmH2O. N = 8 to 10 animals per group.
These differences were not altered by injections of rHuIL-6.

Lung inflammation, edema and injury

BAL fluid and lung histology data are reported in Figs. 3 and 4, respectively. Lung histology is illustrated in Fig. 5. No differences were observed between IL-6KO(MV) and WT(MV) mice, except for the IL-6 concentration in BAL fluid.

As compared to their saline-treated controls (WT(MV) and IL-6KO(MV)), LPS-challenged mice (WT(LPS+MV) and IL-6KO(LPS+MV)) showed higher lung inflammation (as assessed by total cell count and MIP2 concentration in BAL fluid, and histological score of alveolitis, Figs. 3a, c and 4C), lung edema (as assessed by total protein concentration in BAL fluid and histological score of lung congestion, Figs. 3e and 4e), and lung injury (as assessed by global lung injury score, Fig. 4a). The differential cell count in WT(LPS+MV) mice and IL-6KO(LPS+MV) mice showed a strong predominance of neutrophils in both groups (95% [94–97] and 98% [93–99],
respectively; \(p = 0.28\)). IL-6 was detectable only in all WT groups and in the IL-6KO + rHuIL-6 (LPS+MV) group (Fig. 3d).

As compared to WT (LPS+MV) mice, IL-6KO (LPS+MV) mice were more prone to lung inflammation and injury, as shown by a higher total cell count in BAL fluid (8440 [5500–16300] vs. 3860 [1830–5760]; \(p = 0.008\)) (Fig. 3a) and a trend toward a higher global lung injury score (39 [24–50] vs. 26 [24–35]; \(p = 0.190\)). As compared to IL-6KO (LPS+MV) mice, IL-6KO + rHuIL-6 (LPS+MV) mice experienced less severe lung injury, as shown by a lower score of alveolitis [6.0 [4.5–6.5] vs. 12.0 [8.0–12.0]; \(p = 0.007\)] (Fig. 4c), a lower global lung injury score (17 [13–23] vs. 39 [24–50]; \(p = 0.007\)

**Fig. 3** Bronchoalveolar lavage data at the end of a 5-h low tidal volume mechanical ventilation (MV) following either a lipopolysaccharide (LPS) or vehicle (saline) aspiration in wild type (WT) and interleukin-6 knock-out (IL-6KO) mice receiving either recombinant human interleukin-6 (rHuIL-6) or vehicle (saline). a Total cell count of BAL fluid (cell/μL). b TNFα concentration in the BAL fluid (pg/mL). c MIP-2 concentration in the BAL fluid (pg/mL). d IL-6 concentration in the BAL fluid (pg/mL). e Total protein concentration in the BAL fluid (μg/mL). The symbol * denotes Benjamini-Hochberg corrected \(p\) value < 0.05 of Mann–Whitney pairwise comparisons (following Kruskal Wallis test). Data are presented as box and whiskers plots. \(N = 6\) to 8 animals per group.
(Fig. 4a) and a trend toward lower total protein concentration (261 [201–574] vs. 455 [311–719]; \( p = 0.181 \)) and lower scores of lung edema (5.0 [3.0–6.5] vs. 8.0 [6.0–10.5]; \( p = 0.129 \)), leukocyte infiltration (1.0 [1.0–4.5] vs. 6.0 [3.0–10.0]; \( p = 0.081 \)) and congestion (3.0 [3.0–6.5] vs. 10.0 [5.0–12.0]; \( p = 0.083 \)).

**Hemodynamics**

Hemodynamics results are shown in Fig. 6. As compared to saline-treated controls, LPS-challenged mice showed higher heart rate and right ventricular systolic pressure (\( \text{WT}_{(\text{LPS+MV})} \) vs. \( \text{WT}_{(\text{MV})} \) and \( \text{IL-6KO}_{(\text{LPS+MV})} \) vs. \( \text{IL-6KO}_{(\text{MV})} \)). IL-6KO\( _{(\text{LPS+MV})} \) mice had a markedly increased right ventricular systolic pressure (53 [47–60] vs. 37 [33–41]; \( p < 0.001 \)) (Fig. 6a) and a trend toward a higher total pulmonary resistance (2.21 [1.78–2.41] vs. 1.61 [1.37–1.91]; \( p = 0.09 \)) (Fig. 6b) as compared to \( \text{WT}_{(\text{LPS+MV})} \) mice. These differences were completely abolished in IL-6KO mice treated with rHuIL-6 (IL-6KO + rHuIL-6\( _{(\text{LPS+MV})} \) vs. \( \text{WT}_{(\text{LPS+MV})} \)).
Nitric oxide pathway studies

To assess whether the acute pulmonary hypertension observed in IL-6KO mice involved the nitric oxide (NO) pathway, we measured right ventricular systolic pressure (RVSP) during four consecutive periods of hypoxia in WT mice previously treated with rHuIL-6, rHuIL-6 + L-NAME or vehicle. Mice treated with rHuIL-6 showed significantly lower increases in RVSP in response to acute hypoxia as compared to vehicle-treated mice (Fig. 7). The lesser hypoxia-induced pulmonary vasoconstriction was fully prevented by L-NAME administration.

Discussion

We assessed the right-sided hemodynamic and pulmonary effects of IL-6 deficiency in a septic-like double-hit murine model of ARDS. As compared to WT(LPS+MV) mice, IL-6KO(LPS+MV) mice showed a higher BAL cell count, a faster worsening of lung elastic properties during low tidal volume ventilation, and an acute pulmonary hypertension, the latter at least partially attributable to NO-dependent vaso-active mechanisms. IL-6KO + rHuIL-6(LPS+MV) mice experienced less severe lung injury, as shown by lower alveolitis and global lung injury scores, and a lower total pulmonary resistance as compared to IL-6KO(LPS+MV) mice.

The role of IL-6 in ARDS has been actively investigated over the past decades in various rodent models, including hyperoxia [14, 26], inhalation or aspiration of bacterial particles [15, 27], IgG aspiration [28], acid aspiration [29, 30], bacterial pneumonia [16], LPS intratracheal instillation [31] or aerosol inhalation [15] and high tidal volume-associated lung injury [30, 32]. The role of IL-6 was evaluated using IL-6 overexpression [14, 26], recombinant IL-6 administration [15, 16, 28, 32], IL-6-blocking antibodies [28, 32] and IL-6 deficiency [15, 16, 29–32]. However, none of these studies included a model combining septic-like lung injury and protective mechanical ventilation. In the present work, we used a model clinically relevant to ARDS, the double-hit lung injury model [22], which combines LPS aspiration and low tidal volume mechanical ventilation. Lung infection is the most frequent cause of ARDS in humans [1]; low tidal volume ventilation has been shown to be protective during ARDS [33] and is commonly used in clinical practice [34].

Although no formal recommendations are available for ventilatory parameters in mice, we selected a tidal volume of 8 mL/kg, a value that was previously used by several research groups in murine protective mechanical ventilation [35–37]. The duration of low tidal volume mechanical ventilation was adequate as a hit in mice based on previously published work [8]. Our results support the merits of combining LPS and low tidal volume mechanical ventilation to elicit lung inflammation, injury, and an increase in alveolar-capillary permeability in mice. The double hit lung injury model is also characterized by acute pulmonary hypertension [22] and can be
used to assess the consequences of IL-6 deficiency on the pulmonary vascular abnormalities typically seen in ARDS. To this end, we elected to use the model in IL-6 deficient mice and their control wild-type littermates. Surprisingly, we found the IL-6 deficiency to be associated with a lower baseline quasi-static compliance in healthy and LPS-exposed animals. To the best of our knowledge, this phenotype of altered elastic lung properties had not been previously reported. Only one study by Tanaka et al. mentions a trend towards a lower lung compliance in IL-6 deficient mice as compared to wild-type controls [38].

Except for three studies [29–31], most investigations have shown that IL-6 exerts lung protective effects in ARDS [14–16, 26–28, 32]. In our study, there was a progressive worsening of elastic lung properties in wild-type and IL6-KO mice during low tidal volume ventilation, probably because of atelectasis [22, 39]. A new finding from our work is a faster worsening of lung elastic properties in IL-6-KO (LPS+MV) mice as compared to WT (LPS+MV). Furthermore, IL-6KO mice experienced more severe pulmonary inflammation and injury in response to LPS aspiration and mechanical ventilation as compared to wild-type animals. The worst scores of edema, congestion, leukocyte infiltration and alveolitis, and the worst global lung injury score were actually seen in IL-6KO (LPS+MV) mice. In agreement with previous reports [32], treatment with exogenous IL-6 reduced histological lung damage in IL-6KO animals and lessened lung leukocyte infiltration in wild-type mice following challenge with LPS and mechanical ventilation. Furthermore, IL-6KO + rHuIL-6 (LPS+MV) mice showed a trend toward a lower total protein concentration in BAL fluid and lung edema score when compared to IL-6KO (LPS+MV) mice. This observation is consistent with previous reports showing that IL-6 decreases alveolar permeability and lung edema during lung injury [28, 32]. In contrast, exogenous IL-6 did not reverse the heightened BAL inflammation observed in IL-6KO mice challenged with
IL-6 exerts protective effects in extra-pulmonary sepsis models partly through its ability to inhibit apoptosis [20] and promote regeneration of hepatocytes [41]. Intratracheal treatment with recombinant IL-6 has been shown to exert anti-inflammatory effects in mice exposed to intratracheal LPS, with reduced BAL fluid cytokines and lung inflammation [42]. However, results in this research area have not been consistent. Two previous studies in non-septic models of ARDS showed IL-6 had deleterious properties [29, 30]. Another investigation in a double-hit model reported conflicting results. Wild-type mice and IL-6KO mice were subjected to low-dose intratracheal LPS instillation (0.2mg/kg) and 4-h high tidal volume (20mL/kg) mechanical ventilation alone and in combination. As compared to wild-type mice, IL-6KO mice in the combined group showed a significant decrease in bronchoalveolar cellular inflammation and lower histologic scores of lung injury [31]. However, the authors also reported a paradoxical increase in BAL fluid total protein in IL-6KO mice exposed to LPS alone as compared to their WT controls, a finding consistent with our own data. These conflicting observations suggest animal models are important factors to take into consideration when investigating IL-6 effects in ARDS.

ARDS may cause acute pulmonary hypertension [43], a condition associated with poor prognosis in patients [17, 44–46] and potentially worsened by mechanical ventilation, particularly when high PEEP [47] or high-frequency oscillatory ventilation [48] is used. The mechanism of this pulmonary vascular dysfunction is multifactorial, including partially dysregulated vasoreactivity [49]. In IL-6KO (LPS+MV) animals, we observed an increase in total pulmonary resistance, as compared to WT (LPS+MV) mice and IL-6KO + rHuIL-6 (LPS+MV) mice. We hypothesized that the acute pulmonary hypertension observed in our study could be related to a dysregulation of NO-dependent vasoactive mechanisms. Several studies have shown that IL-6 exerts acute systemic hemodynamics effects through this pathway. The acute administration of IL-6 produced a transient dose-dependent systemic hypotension in rats [50]. In vitro, acute exposure of hamster papillary muscles [51] or cardiomyocytes [52] to IL-6 reduced contractility. This acute negative inotropic effect may result from an activation of endothelial NO synthase (eNOS) and inducible NO synthase (iNOS) [53], with a downstream decrease in intracellular Ca++ influx [54]. Other studies have suggested that IL-6, in association with IL-1β, is implicated in the NOS-dependent systemic vasodilatation seen during sepsis [55]. In the present study, rHuIL-6 treatment in healthy wild-type, hypoxia-challenged mice reduced hypoxic pulmonary vasoconstriction. This result is in agreement with in another paper by our team, which described a trend toward a higher hemodynamic response to acute LPS and mechanical ventilation. Taken together, these data suggest differential effects of IL-6 in lung tissue and alveolar spaces [32].

Protective effects of IL-6 have been mostly reported in septic and septic-like induced ARDS. In addition to promoting inflammation, lung damage and edema, IL-6 deficiency alters bacterial clearance in experimental pneumonia [16, 40] and is associated with increased mortality following LPS aspiration [15]. Furthermore,
hypoxia (5 min) in IL-6KO mice as compared to WT mice; conversely, IL-6-KO mice exhibited a lower right ventricular systolic pressure in response to chronic hypoxia (2 weeks) as compared to WT mice [56].

Because both eNOS and iNOS contribute to pulmonary vascular tone and modulate hypoxic pulmonary vasoconstriction [57], we tested the effects of the non-selective NOS inhibitor L-NAME. Its co-administration with rHuIL-6 totally restored hypoxic pulmonary vasoconstriction. This finding suggests a role for NOS isoforms in mediating the IL-6-induced inhibition of hypoxic pulmonary vasoconstriction. Therefore, the acute pulmonary hypertension observed during lung injury in LPS-exposed mice lacking endogenous IL-6 may be attributed in part to vasoactive mechanisms involving a dysregulation of NOS isoforms. This hypothesis will have to be fully investigated in future studies. Of note, the effects of IL-6-related inhibition of hypoxic pulmonary vasoconstriction may be considered either beneficial on right-sided hemodynamics or deleterious on gas exchange. The clinical relevance of these changes must be kept in mind when debating the potential therapeutic applications of rHuIL-6 in patients with ARDS.

The hemodynamic changes observed in IL-6KO (LPS +MV) mice may cause further lung injury and/or inflammation via a direct mechanism. Several studies support this conclusion. Following pulmonary artery banding to induce pre-capillary pulmonary hypertension and subsequent right heart failure in mice, Vistnes et al. quantified circulating cytokines levels and observed an increase in IL-1α, IL-6, G-CSF and CXCL9 as compared to sham operated mice [58]. In another study, Costa-Souza et al. induced pre-capillary pulmonary hypertension and quantified pulmonary inflammation in a rat model of microsphere-induced pulmonary embolism. The authors observed an increase in bronchoalveolar neutrophils as compared to control rats [59]. Taken together, the results from these two non-septic rodent models of acute pre-capillary pulmonary hypertension suggest the elevated right ventricular systolic pressure (or pulmonary arterial pressure) might contribute directly to pulmonary and systemic inflammation. Previous work from our research group suggests additional factors may be involved. In a LPS-challenged mouse model, 5-h mechanical ventilation using low tidal volume inflation alone or in combination with intermittent deep inflations produced a significant rise in right ventricular systolic pressures and pulmonary vascular resistance. However, we did not observe any increase in lung and systemic inflammation [22].

Our study has several limitations. First, we did not measure systemic blood pressure, and assumed no differences were present between groups. This assumption is reasonable considering previously available results showing that baseline systemic blood pressure is similar in WT and IL-6KO mice [60]. Second, we also assumed that left-sided myocardial function and pressures did not differ between groups. This assumption is supported by previous findings that intravenous exogenous IL-6 exerts only very transient left-sided hemodynamic effects in rodents [50].

Conclusions

In a septic-like double-hit murine model of ARDS (LPS aspiration followed by 5-h low tidal volume mechanical ventilation), we found that IL-6 deficiency caused a more severe bronchoalveolar cellular inflammation and a faster deterioration of lung elastic properties during low tidal volume ventilation. This higher severity was partially reversed by exogenous IL-6, which mitigated the histological injury observed in IL-6 deficient mice challenged with LPS and mechanical ventilation. Furthermore, IL-6 deficiency was associated with marked acute pulmonary hypertension, which was prevented by exogenous IL-6 administration. IL-6 acted as limiting the hypoxic pulmonary vasoconstriction, most probably by regulating the NO pathway. Future studies are needed to reconcile the discrepancy between the commonly recognized merits of using IL-6 concentrations as a detrimental prognostic factor in sepsis in a clinical setting and its protective role in experimental sepsis and ARDS.

Abbreviations

ALI: Acute lung injury; ARDS: Acute respiratory distress syndrome; BAL: Broncho-alveolar lavage; eNOS: Endothelial nitric oxide synthase; IL-6: Interleukin-6; IL-6KO: Interleukin-6 knock-out; iNOS: Inducible nitric oxide synthase; L-NAME: Nω-nitro-L-arginine methyl ester hydrochloride; rHuIL-6: Recombinant human interleukin-6; RVSP: Right ventricular systolic pressure; WT: Wild-type

Acknowledgments

None.

Funding

GV was a recipient from the Fondation de Recherche Médicale (FRSM) and from the Fond de Recherche en Santé Respiratoire (FRSR). The Academy of Paris (Legs Poix) provided a supplementary grant to support the study.

Availability of data and materials

All data generated and analyzed during the study are included in the published article and can be shared upon request.

Authors’ contributions

GV had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of its analysis. GV participated in the design of the study, conducted the animal studies, participated in the data acquisition, analysis and interpretation, and the statistical analysis, and drafted the manuscript. KR participated in the animal studies, the data acquisition, analysis and interpretation, and helped to draft the manuscript. VA participated in the biological studies, the data acquisition, analysis and interpretation, and helped to draft the manuscript. JT VN conducted the histological analysis and helped to revise the manuscript. SHA participated in the biological studies, the data acquisition, analysis and interpretation. SEA participated in the design of the study, the data analysis and interpretation, and helped to revise the manuscript. AMD and BM designed the study, participated in the data analysis and interpretation, and the statistical analysis, and revised the manuscript.
Competing interests
The authors have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Consent for publication
Not applicable

Ethics approval and consent to participate
All animal care and procedures were approved by the Institutional Animal Care Committee (Comité d’Ethique en Matière d’Expérimentation Animale, ComEth ANSES/ENVA/UPEC), in accordance with the official guidelines of the French Ministry of Agriculture for the experimental use of animals.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1INSERM, Unité U955 (Institut Mondor de Recherche Biomédicale), Créteil, France. 2Faculté de Médecine, Groupe de recherche clinique CARMAS, Université Paris Est, Créteil, France. 3Groupe Henri Mondor-Albert Chenevier, Hôpital Henri Mondor, Service de Réanimation Médicale, AP-HP, Créteil, France. 4Groupe Henri Mondor-Albert Chenevier, Hôpital Henri Mondor, Service d’Anatomie et Cytologie Pathologiques, AP-HP, Créteil, France. 5Groupe Henri Mondor-Albert Chenevier, Hôpital Henri Mondor, Service des Explorations Fonctionnelles, AP-HP, Créteil, France.

Received: 26 September 2016 Accepted: 13 April 2017

Published online: 19 April 2017

References
1. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353(16):1685–93.
2. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1334–49.
3. Gaidant RA, Patterson PH. Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Stem Cells. 1999;17(3):127–37.
4. Fantuzzi G, Ghezzi P, Poli V. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med. 1994;180(4):1243–52.
5. Ermolaeva M, Veldhuizen R, Slutsy AS, Joseph M, McGaugh L. Effects of mechanical ventilation of isolated mouse lungs on surfactant and inflammatory cytokines. Eur Respir J. 2001;17(3):488–94.
6. Stuber F, Wrigge H, Schroeder S, Wettegrove S, Zinnerling J, Hoeft A, Putensen C. Kinetic and reversibility of mechanical ventilation-associated pulmonary and systemic inflammatory response in patients with acute lung injury. Intensive Care Med. 2002;28(7):834–41.
7. Vapnikov K, Voloskak G, Pliniannak G, Kondii E, Koutsoupoulos A, Tsatsanis C, Georgopoulos D. Effects of respiratory rate on ventilator-induced lung injury at a constant PaCO2 in a mouse model of normal lung. Crit Care Med. 2006;34(6):1277–83.
8. Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, Brienza A, Bruno S, Slutsy AS. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1999;282(15):154–61.
9. Parsons PE, Eiser MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, Wheeler AP. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med. 2005;33(1):1–6. discussion 230–232.
10. Frank JA, Parsons PE, Matthay MA. Pathogenetic significance of biological markers of ventilator-associated lung injury in experimental and clinical studies. Chest. 2006;130(6):1906–14.
11. Frank JA, Parsons PE, Matthay MA. Pathogenetic significance of biological markers of ventilator-associated lung injury in experimental and clinical studies. Chest. 2006;130(6):1906–14.
12. Remick DG, Bolgos C, Copeland S, Siddiqui J. Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect Immun. 2005;73(5):2751–7.
13. O’Malley K, Moldawer L. Interleukin-6: Still after all these years. Crit Care. 2006;34(10):2690–1.
14. Ward NS, Waxman AB, Homer RJ, Mantell LL, Einarrison O, Du Y, Elias JA. Interleukin-6-induced protection in hyperoxic acute lung injury. Am J Respir Cell Mol Biol. 2000;22(5):535–42.
15. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK. IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998;101(2):311–20.
16. Jones MR, Quinton LJ, Simms BT, Lupa MM, Kogan MS, Mignard JP. Roles of interleukin-6 in activation of STAT proteins and recruitment of neutrophils during Escherichia coli pneumonia. J Infect Dis. 2006;193(3):360–9.
17. Bull TM, Clark B, McKinnon K, Moss M, National Institutes of Health/National Heart, Lung, and Blood Institute ARDS Network. Pulmonary vascular dysfunction is associated with poor outcomes in patients with acute lung injury. Am J Respir Crit Care Med. 2010;182(2):1123–8.
18. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kissimoto T, Zinkemagel R, Bluthmann H, Köhler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368(6469):339–42.
19. Yardeni T, Eickhaus M, Morris HD, Huidting M, Hoogstraten-Miller S. Retro-orbital injections in mice. Lab Ani. 2011;140(3):155–60.
20. Arkan AA, Yu B, Mastrangelo MA, Tweardy DJ. Interleukin-6 treatment reverses apoptosis and blunts susceptibility to intraperitoneal bacterial challenge following hemorrhagic shock. Crit Care Med. 2006;34(3):771–7.
21. Matsushita K, Iwanaga S, Toda K, Kimura K, Shimada M, Sano M, Umezawa A, Hata J, Ogawa S. Interleukin-6 soluble interleukin-6 receptor complex reduces pulmonary fibrosis via inhibiting myocardial apoptosis. Lab Invest. 2005;85(10):1210–23.
22. Mekontso Essap A, Voiriot G, Zhou T, Marcos E, Dudek SM, Jacobson JR, Machado R, Adnot S, Brochard L, Maire B, Garcia JG. Conflicting physiological and genomic cardiopulmonary effects of recruitment maneuvers in murine acute lung injury. Am J Respir Cell Mol Biol. 2012;46(4):541–50.
23. Champion HC, Willhaye DJ, Tower A, Kadowitz PJ, Hyman AL. A novel right-heart catheterization technique for in vivo measurement of vascular responses in lungs of intact mice. Am J Physiol Heart Circ Physiol. 2000;278(1):H8–H15.
24. Belperio JA, Keane WP, Burdick MD, Londhe V, Yue YY, Li K, Phillips RJ, Stierer RM. Critical role of CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury. J Clin Invest. 2002;110(11):1703–16.
25. Nishina K, Mikawa K, Takao Y, Shiga M, Maekawa N, Obara H. Intravenous lidocaine attenuates acute lung injury induced by hydrochloric acid aspiration in rabbits. Anesthesiology. 1998;88(5):1300–9.
26. Kolliputi N, Waxman AB. IL-6 cytoprotection in hyperoxic acute lung injury occurs via suppression of cytokine signaling-1 induced apoptosis signal-regulating kinase-1 degradation. Am J Respir Cell Mol Biol. 2009;40(3):314–24.
27. Leemans JC, Vervoordeldonk MJBM, Florquin S, van Kessel KP, van der Poll T. Differential role of interleukin-6 in lung inflammation induced by lipopolysaccharide and peptidoglycan from Staphylococcus aureus. Am J Respir Crit Care Med. 2002;165(10):1445–50.
28. Sharley TP, Foreback JL, Remig DG, Ullrich TR, Kunkel SL, Ward PA. Regulatory effects of interleukin-6 in immunoglobulin G immune-complex-induced lung injury. Am J Pathol. 1997;151(11):193–203.
29. Imai Y, Kuba K, Neely GG, Yaghoubian-Malhami R, Perkman T, van Loo G, Ernolaeva M, Veldhuisen R, Leung YH, Wang H, Liu H, Sun Y, Pasparakis M, Kopf M, Mech C, Bavari S, Peiris JS, Slutsy AS, Akira S, Hultqvist M, Holmdahl R, Nicholls J, Jiang C, Binder CJ, Penninger JM. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133(2):235–49.
30. Gurkan OU, He C, Zelinski R, Rabb H, King LS, Dodd-o IM, D’Alessio FR, Aggarwal N, Pearse D, Becker PM. Interleukin-6 mediates pulmonary vascular permeability in a two-hit model of ventilator-associated lung injury. Exp Lung Res. 2011;37(10):575–84.
31. Goldman JL, Sammon S, Kempf C, Saadat L, Letsiou E, Wang T, Moreno-Vinasco L, Rizzo AN, Fortman JD, Garcia JG. Pleiotropic effects of interleukin-6 in a “two-hit” murine model of acute respiratory distress syndrome. Pulm Circ. 2014;4(2):280–8.
32. Wolters PJ, Voy A, Sutherland RE, Kim SS, Koff J, Mao Y, Frank JA. Neutrophil-derived IL-6 limits alveolar barrier disruption in experimental ventilator-induced lung injury. J Immunol. 2009;182(12):6056–62.
33. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for...
acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301–8.

34. Esteban A, Ferguson ND, Meade MO, Frutos-Vivar F, Apezteguia C, Brochard L, Raymondos K, Nin N, Hurtado J, Tomicic V, Gonzalez M, Elizalde J, Nightingale P, Abrug F, Pelosi P, Arabi Y, Moreno R, Jibaja M, D’Empaire G, Sandi F, Manzim D, Montsher AM, Anzueto A. Evolution of mechanical ventilation in response to clinical research. Am J Respir Crit Care Med. 2008;177(2):170–7.

35. Halbertsma FJ, Vaneker M, Pickkers P, Snijdelaar DG, van Egmond JG, Scheffer GJ, van der Hoeven HG. Hypercapnic acidosis attenuates the pulmonary innate immune response in ventilated healthy mice. Crit Care Med. 2008;36(8):2403–6.

36. Manisits NA, Kardara M, Hechimovitch D, Letsiou E, Castellon M, Roussos C, Shinin V, Votta-Vellis E, Schwartz DE, Minshall RD. Role of caveolin-expression in the pathogenesis of pulmonary edema in ventilator-induced lung injury. Pulm Circ. 2012;2(4):452–60.

37. Manisits NA, Kardara M, Hechimovitch D, Letsiou E, Castellon M, Roussos C, Shinin V, Votta-Vellis E, Schwartz DE, Minshall RD. Role of caveolin-expression in the pathogenesis of pulmonary edema in ventilator-induced lung injury. Pulm Circ. 2012;2(4):452–60.

38. Manisits NA, Kardara M, Hechimovitch D, Letsiou E, Castellon M, Roussos C, Shinin V, Votta-Vellis E, Schwartz DE, Minshall RD. Role of caveolin-expression in the pathogenesis of pulmonary edema in ventilator-induced lung injury. Pulm Circ. 2012;2(4):452–60.

39. Allen GB, Suratt BT, Rinaldi L, Petty JM, Bates JHT. Choosing the frequency of deep inflation in mice: balancing recruitment against ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2006;291(4):L710–717.

40. Dalrymple SA, Slattery R, Aud DM, Krishna M, Lucian LA, Murray R. The effect of IL-6 on cardiac contractility in isolated guinea pig heart. J Appl Physiol. 2010;108(5):1357–64.

41. Deutschman CS, Cereda M, Ochroch EA, Raj NR. Sepsis-induced cholestasis, impaired hepatic cellular function during high-frequency oscillatory ventilation in adults with acute respiratory distress syndrome. A multivariate analysis. Am J Respir Crit Care Med. 2008;177(10):Pt 1):L472–478.

42. Bhargava R, Janssen W, Altmann C, Andres-Hernando A, Okamura K, Elizalde J, Nightingale P, Abroug F, Pelosi P, Arabi Y, Moreno R, Jibaja A, Jardin F. Acute cor pulmonale in acute respiratory distress syndrome (ARDS). A prospective, blinded mechanistic study in mechanically ventilated ICU patients. J Crit Care. 2013;28(3):495–500.

43. Bhargava R, Janssen W, Altmann C, Andres-Hernando A, Okamura K, Elizalde J, Nightingale P, Abroug F, Pelosi P, Arabi Y, Moreno R, Jibaja A, Jardin F. Acute cor pulmonale in acute respiratory distress syndrome (ARDS). A prospective, blinded mechanistic study in mechanically ventilated ICU patients. J Crit Care. 2013;28(3):495–500.

44. Villar J, Blazquez MA, Lubillo S, Quintana J, Manzano JL. Pulmonary innate immune response in ventilated healthy mice. Crit Care Med. 2008;36(8):2403–6.

45. Villar J, Blazquez MA, Lubillo S, Quintana J, Manzano JL. Pulmonary innate immune response in ventilated healthy mice. Crit Care Med. 2008;36(8):2403–6.

46. Boissier F, Katsahian S, Razazi K, Thille AW, Roche-Campo F, Leon R, Vivier E, Boissier F, Katsahian S, Razazi K, Thille AW, Roche-Campo F, Leon R, Vivier E, Bhagat K, Hingorani AD, Palacios M, Charles IG, Vallance P. Cytokine-induced venodilatation in humans in vivo: eNOS masking as iNOS. Cardiovasc Res. 1999;41(3):754–6.

47. Saalvare L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S, Eddahibi S. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res. 2009;10:6.

48. Fagan KA, Tyler RC, Sato K, Fouty BW, Morris Jr KG, Huang PL, McMurtry IF, Rodman DM. Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. Am J Physiol. 1999;277(3 Pt 1):L472–478.

49. Vistnes M, Waehre A, Nygård S, Sjaastad I, Anderson KB, Husberg C, Christensen G. Circulating cytokine levels in mice with heart failure are etiology-dependent. J Appl Physiol. 2010;108(5):1357–64.

50. Souza-Costa DC, Figueiredo-Lopes L, Alves-Filho JC, Semprini MC, Gerlach RF, Cunha FQ, Tanus-Santos JE. Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloprotease-9. Crit Care Med. 2007;35(1):239–45.

51. Schrader U, Kinzienbaw DA, Johnson AW, Faraci FM, Didion SP. IL-6 deficiency protects against angiotensin II induced endothelial dysfunction and hypertrophy. Arterioscler Thromb Vasc Biol. 2007;27(12):2576–81.